AC   CVCL_L297
DR   cancercelllines; CVCL_L297
DR   GEO; GSM966944
DR   Progenetix; CVCL_L297
DR   Wikidata; Q54900912
RX   PubMed=19528452;
RX   PubMed=29444910;
RX   PubMed=31548718;
CC   Problematic cell line: Misclassified. Originally thought to arise from a metastatic carcinoid of the terminal ileum but shown to be an EBV-transformed lymphoblastoid cell line (PubMed=29444910; PubMed=31548718).
CC   Doubling time: ~2 days (PubMed=19528452).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: SNP array analysis.
CC   Derived from site: In situ; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): PubMed=29444910
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 8,13,14
ST   D16S539: 12,13
ST   D21S11: 28,29,30
ST   D5S818: 11,12
ST   D7S820: 10,12
ST   TH01: 6,9,9.3
ST   TPOX: 8
ST   vWA: 14,17,18,19
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_L296 ! H-STS
OI   CVCL_L298 ! P-STS
SX   Male
AG   42Y
CA   Transformed cell line
DT   Created: 06-05-13; Last updated: 05-10-23; Version: 17
RX   PubMed=19528452;
RA   Pfragner R., Behmel A., Hoger H., Beham A., Ingolic E., Stelzer I.,
RA   Svejda B., Moser V.A., Obenauf A.C., Siegl V., Haas O., Niederle B.;
RT   "Establishment and characterization of three novel cell lines -- P-STS,
RT   L-STS, H-STS -- derived from a human metastatic midgut carcinoid.";
RL   Anticancer Res. 29:1951-1961(2009).
RX   PubMed=29444910; DOI=10.1530/ERC-17-0445;
RA   Hofving T., Arvidsson Y., Almobarak B., Inge L., Pfragner R.,
RA   Persson M., Stenman G., Kristiansson E., Johanson V., Nilsson O.;
RT   "The neuroendocrine phenotype, genomic profile and therapeutic
RT   sensitivity of GEPNET cell lines.";
RL   Endocr. Relat. Cancer 25:367-380(2018).
RX   PubMed=31548718; DOI=10.1038/s41588-019-0490-z;
RA   Hofving T., Karlsson J., Nilsson O., Nilsson J.A.;
RT   "H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines.";
RL   Nat. Genet. 51:1426-1427(2019).